Adaptimmune T-cell platform delivers initial responses in 4 solid tumors

Adaptimmune Therapeutics (NASDAQ:ADAP) is up 60% premarket after reporting two confirmed Partial Responses (PRs) – one in a patient with liver cancer and one in a patient with melanoma.

There are also two unconfirmed PRs – one in a patient with gastro‑esophageal junction cancer and one in a patient with head and neck cancer. These data further confirm the potential of company’s SPEAR T-cell platform for patients with multiple solid tumors.

A decrease of 100% and 42% in target lesions was observed in a patient with hepatocellular carcinoma and metastatic rectal mucosal melanoma, respectively.

A decrease of 42% and 36% in target lesions was seen in a patient with metastatic gastro-esophageal junction cancer and head and neck cancer treated in the expansion phase of the Phase 1 ADP A2M4 trial, respectively.

#JPM20

https://seekingalpha.com/news/3531197-adaptimmunes-spear-t-cell-platform-delivers-initial-responses-in-four-solid-tumors-shares-up